Who is in your network?

Pet DNA Testing Market is anticipated to hold a share of US$ 839.84 million by 2033

The Pet DNA Testing Market is anticipated to expand its roots at a steady CAGR of 9.1% between 2023 and 2033. The market is anticipated to cross a market share of US$ 839.84 million by 2033 while it is likely to be valued at US$ 351.52 million in 2023.

Increased adoption of dogs and cats post-pandemic along with people treating their pets as family members is fueling the demand for pet DNA testing solutions. Furthermore, the higher veterinary budget is also expanding the research and development facilities.

Expanding breeding businesses and end users buying dogs of foreign breeds. Moreover, conducting breed origin tests is also fueling the demand for pet DNA tests. Apart from the breed identification possible genetic threats could also be found through the test.

The integration of veterinary technology with the digitization of veterinary healthcare along with dog breed tests.

People are curious to know more about their pets, ancestral history, and characteristics. These details optimize their diet regime and exercise which fuels the sales of pet DNA tests.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsigh....ts.com/reports/sampl

Key Points:

The United States market leads the pet DNA testing market in terms of market share in North America. The North American market held a market share of 35.0% in 2022. The market growth is attributed to the increase in pet care units and pet humanization.

The United Kingdom pet DNA testing market is another significant market from the European region. Regional growth is attributed to government efforts and, advancements in pet genetics technology.

The Chinap pet DNA testing market is anticipated to thrive at a healthy CAGR during the forecast period. The growth is owed to increased pet adoption, advanced DNA testing, and expanding breeding business.

By test type, the genetic diseases segment held a share of 35.0% in 2022. This is due to the increased amount of information and potential health threats.

Competitive Landscape:

The key vendors work on producing pet DNA testing solutions with higher accuracy, small diagnostics time, and affordable pricing. The market players also focus on creating easy-to-use products. Key competitors are indulged in mergers, acquisitions, and partnerships to increase their supply chain and distribution channel. The key players in the market are Wisdom Panel (Mars, Inc.); Embark Veterinary, Inc.; Dognomics (Clinomics); Basepaws, Inc. (Zoetis); and NeoGen Corp.

Recent Market Developments:

Wisdom panel introduced a `wisdom panel dog DNA test for breed detection. The test delivers information such as the dog’s color, strength, energy, and fur.

Embark Veterinary launched tests involving breed identification, health and wellness tests, and faster test results.

Dognomics dog DNA tests have eased their testing procedures with three simple steps: sign up, swab, and send. While swabbing takes 5-10 secs, the company has free shipping in the United States.

Market Segmentation:

Animal Type Outlook:

Dogs

Cats

Sample Type Outlook:

Blood

Saliva

Semen

Others

Test Type Outlook:

Breed Profile

Genetic Diseases

Health & Wellness

End User Outlook:

Pet Owners

Breeders

Veterinarians

Key Regions Covered:

North America

United States

Canada

Latin America

Brazil

Mexico

Rest of Latin America

Europe

Germany

United Kingdom

France

Spain

Russia

Rest of Europe

Japan

Asia Pacific Excluding Japan

China

India

Malaysia

Singapore

Australia

Rest of APEJ

The Middle East and Africa

GCC Countries

Israel

South Africa

Rest of Middle East and Africa

Know the power of Matka play with Matka Bookings! Explore our new online Matka Play website and Matka Booking App for a revolutionary Satta Matka experience in 2023. Enjoy the best online Matka play with real-time support, a seamless 500 deposit, and unmatched excitement. Play smarter, win bigger!


Ref. Link: https://tinyurl.com/3xrc4edc

Satta Matka is a popular game of chance in India that has been around for decades. It is a game that involves betting on numbers and winning big if you get lucky.

Ref. Link: https://tinyurl.com/mr47xdzx

Hepatic Encephalopathy Treatment Market, Anticipating US$ 2971.51 Million by 6.5% CAGR by 2033

During the forecast period 2023 to 2033, the Hepatic Encephalopathy Treatment Market is expected to grow at a value of 6.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Hepatic encephalopathy treatment is expected to rise up to a market valuation of US$ 2971.51 Million. The growth of the market can be attributed to the increasing prevalence of liver diseases such as cirrhosis and non-alcoholic fatty liver disease (NAFLD).

One of the key factors driving the growth of the Hepatic Encephalopathy Treatment Market is the development of new and innovative treatments for HE. In recent years, several new medications have been approved for the treatment of HE, including rifaximin, lactulose, and neomycin. These medications work by reducing the levels of toxins in the gut or preventing their absorption into the bloodstream, which can help reduce the severity of HE symptoms.

Acquire a stunning sample report featuring compelling graphs and charts. @
https://www.futuremarketinsigh....ts.com/reports/sampl

Another factor driving the growth of the Hepatic Encephalopathy Treatment Market is the increasing awareness and diagnosis of HE. As the prevalence of liver diseases such as cirrhosis and NAFLD continues to rise, more individuals are being diagnosed with HE and seeking treatment. In addition, advancements in diagnostic technologies have made it easier for healthcare professionals to identify HE in its early stages, allowing for earlier intervention and better outcomes.

Key Takeaways from the Market Study:

The Hepatic encephalopathy treatment market is expected to grow at a value of 6.5% CAGR in the forecast period 2023-2033
Hospital pharmacies are expected to hold 49% of the market share in 2023 for Hepatic encephalopathy treatment market.
North America is expected to possess 44% market share for Hepatic encephalopathy treatment market in 2023.
Asia Pacific Hepatic encephalopathy treatment market size is expected to possess 39% market share in 2023.
“The Hepatic Encephalopathy Treatment Market is also being driven by the increasing adoption of combination therapies for HE.” states an FMI analyst

Competitive Landscape:

Key players in the hepatic encephalopathy treatment market are Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc.

Mallinckrodt Pharmaceuticals has developed and marketed several medications for the treatment of Hepatic Encephalopathy that include Ofirmev and Terlipressin (Glypressin) injection. In addition to these medications, Mallinckrodt Pharmaceuticals has also sponsored clinical research into the treatment of HE, with a focus on developing new treatments and improving the understanding of the condition.
Salix Pharmaceuticals has developed Xifaxan (rifaximin) tablets. Xifaxan is an antibiotic medication that works by reducing the levels of bacteria in the gut, which can help reduce the production of toxins that contribute to the development of HE.
Gain valuable insights through our cutting-edge methodology today. @
https://www.futuremarketinsigh....ts.com/request-repor

Key Segments Profiled in the Hepatic Encephalopathy Treatment Industry Survey

Drug Class:

Antibiotics
Laxatives
L-ornithine
L-aspartate
Diagnosis:

Blood Tests
CT Scan
Liver Functioning Tests
Route of Administration:

Oral
Injectable
Intravenous
Others
Distribution Channel:

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Progressive Multifocal Leukoencephalopathy Treatment Market is anticipated to reach US$ 1,773.97 million by 2033

The global Progressive Multifocal Leukoencephalopathy Treatment Market revenue is predicted to generate a value of US$ 1,320 million in 2023 and a market value of US$ 1,773.97 million by 2033, with a CAGR of 3% from 2023 to 2033. From 2018 to 2022, the market for Progressive Multifocal Leukoencephalopathy Treatment grew at a 2% CAGR.

According to the most recent research, PML affects around one in every 200,000 people. According to the same article, it is projected that 4,000 persons in the United States and Europe get PML each year. The rising demand for these therapies is projected to spur the development of new and innovative treatments, propelling the industry forward in the coming years.

North America is expected to gain a market share of around 40% throughout the projection period. This increase is due to the increasing incidence of the illness in the region. Furthermore, government efforts and an increase in the number of research collaborations are encouraging market expansion in North America. Because of a shift towards point-of-care healthcare, Asia Pacific is a booming market. The growing number of hospitals in India and China creates a global business opportunity.

The Sample report is available in PDF format@ https://www.futuremarketinsigh....ts.com/reports/sampl

Key Takeaways from the Market Study

The Progressive Multifocal Leukoencephalopathy Treatment market increased at a 2% CAGR from 2018 to 2022.

From 2023 to 2033, the global Progressive Multifocal Leukoencephalopathy Treatment market is estimated to rise at a 3% CAGR.

The Progressive Multifocal Leukoencephalopathy Treatment Market is anticipated to be worth US$ 1773.97 million by 2033.

Hospital pharmacies have the biggest market share, according to the FMI research.

North America is estimated to have 40% of the market for Progressive Multifocal Leukoencephalopathy Treatment.

The South and East Asia market is expected to grow significantly throughout the projected period, accounting for 20% of the total.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Progressive Multifocal Leukoencephalopathy Treatment.” says an FMI analyst

Market Competition

Key players in the market include pharmaceutical companies such as NeoImmuneTech, Neurimmune, GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc., Novartis AG, AbbVie Inc., and Bristol-Myers Squibb Company along with healthcare providers and technology companies among other global players.

In October 2022, Cellevolve Bio, Inc., a company focused on developing and commercializing cell therapies, announced that its Investigational New Drug (IND) application for CE-VST01-JC has been approved by the US Food and Drug Administration (FDA). CE-VST01-JC is a JC Virus Specific T Cell Therapy that is being studied for the treatment of progressive multifocal leukoencephalopathy (PML) and has received orphan drug designation from the FDA.

The safety and effectiveness of CE-VST01-JC will be tested in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 study called ASCEND-JC. The study is expected to enroll up to 60 patients across the US, Canada, and EU, with the first patient enrollment anticipated in the first half of 2023.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Progressive Multifocal Leukoencephalopathy Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of indication, treatment, distribution channel, end-users and region.

Key Segments Profiled in the Progressive Multifocal Leukoencephalopathy Treatment Industry Survey

Treatment:

Anti-retroviral Therapy

Antiviral/Anti JCV

Other Symptomatic

Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Indication:

HIV/AIDS

Organ Transplantation

Multiple Sclerosis

Hematologic Malignancies

Medical Waste Management System Market Anticipated to Grow at 6.6% CAGR, Valued at US$ 15,336.9 Million by 2033

Anticipate the global medical waste management system market to reach a valuation of US$ 8,094 million by the year 2023. Over the decade following 2023, there is a strong expectation of sustained demand for medical waste management systems, with a projected Compound Annual Growth Rate (CAGR) of 6.6%. This trajectory is set to culminate in a substantial market worth of approximately US$ 15,336.9 million by 2033.

The term “medical waste” encompasses waste materials generated within medical facilities and life science processing companies. This category of waste includes a wide spectrum of items such as body parts, blood, chemicals, diverse materials, and various medical devices. These items range from used needles, syringes, and soiled dressings to diagnostic samples, pharmaceuticals, and even radioactive materials.

Request a Sample Copy of the Report now
https://www.futuremarketinsigh....ts.com/reports/sampl

Key Takeaways from Medical Waste Management System Market

North America holds more than 30% of the market share due to rising number of patients in the US and Canada coupled with strict rules/regulations set by government bodies.

Europe holds more than 25% of the market share due to growing demand for medical waste management systems to properly treat, dispose, and recycle medical waste.

The Asia-Pacific is expected to grow at the fastest rate in the medical waste management system market sue to numerous start-ups coming up with e-disposal solution for managing infectious waste.

“Increasing incidences of chronic ailments that need longer hospital stays, emphasis on medical waste management in the developing as well as developed countries, and strict regulations laid down by the government regarding appropriate medical waste disposal are the primary drivers to Medical Waste Management System Market”, says an analyst from Future Market Insights.

Competitive Landscape

Envetec Sustainable Technologies Ltd., in February 2022, tabled GENERATIONS technology, which comes across as one of the breakthrough cleantech solutions safely treating biohazardous materials and waste, inclusive of glass, plastics, sharp containers, PPE, and the other general laboratory consumables.

MediWaste was launched in March 2022 for handling biohazardous waste in Bermuda. Its functionalities include treating, transportation, and disposal of medical waste via two incinerators specifically designed for the serving the purpose mentioned above.

The United Nations Development Programme (UNDP), in collaboration with the Government of Japan, came up with a novel project in August 2022 for supporting various national health agencies with other stakeholders in Bhutan, Bangladesh, and Maldives for addressing an uncontrollable increase in infectious healthcare waste resulting out of the pandemic.

TerraConsult, in April 2019, merged with ByrneLobby for expanding its geographical presence.

Stericycle, in February 2020, made an announcement about inking an agreement with Harso Corporation about selling its business pertaining to Domestic Environments Solutions for US$ 462.5 Million.

Clean Harbors, in August 2021, completed acquisition of HydroChemPSC for US$ 1.25 Billion with the objective of strengthening the opportunities of strong customer service and brand equity.

Key Players:

BioMedical Waste Solutions LLC

Bondtech Medical Waste Containers

Clean Harbors, Inc.

Converge Medical Solutions LLC

Daniels Sharpsmart Inc.

Stericycle, Inc.

Medasend Biomedical, Inc.

Mazaya Waste Management LLC

Sharps Compliance, Inc.

Veolia Environment S.A.

REMONDIS Medison GmbH

Republic Services, Inc.

Waste Management, Inc.

Suez Environment S.A.

What does the Report unveil?

Future Market Insights offers an exclusive perspective and various real-time insights on the medical waste management system market in its latest study, presenting historical demand assessment of 2016 to 2021 and projections for 2022 to 2032.

The research study is based on service (medical waste treatment, disposable medical waste management, and medical waste recycling), by medical waste (bio hazardous medical waste management system, non-hazardous medical waste management system, sharps medical waste management system, pharmaceutical medical waste management system, radioactive medical waste management system, and other medical waste types management system), by services site (onsite medical waste management services and offsite medical waste management services), by treatment (medical waste management through incineration, medical waste management through autoclaving, medical waste management through chemical treatment, and medical waste management through other approaches), and waste generator (medical waste management system for hospitals, medical waste management system for clinics, medical waste management system for Ambulatory Surgical Centers, medical waste management system for pharmaceutical companies, medical waste management system for biotechnology companies, and medical waste management system for other waste generators).

With an ever-increasing number of government-sponsored programs hitting the floor, the medical waste management system market is bound to be unstoppable in the years to come. The government agencies adhering to regulations include the US FDA, CDC, OSHA (Occupational Safety and Health Administration), DOT (Department of Transport), and DEA (Drug Enforcement Administration).

Key Segments Covered in the Medical Waste Management System Industry Analysis

By Services:

Medical Waste Treatment

Disposable Medical Waste Management

Medical Waste Recycling

By Medical Waste:

Bio Hazardous Medical Waste Management System

Non Hazardous Medical Waste Management System

Sharps Medical Waste Management System

Pharmaceutical Medical Waste Management System

Radioactive Medical Waste Management System

Other Medical Waste Types Management System

By Services Site:

Onsite Medical Waste Management Services

Offsite Medical Waste Management Services

By Treatment:

Medical Waste Management through Incineration

Medical Waste Management through Autoclaving

Medical Waste Management through Chemical Treatment

Medical Waste Management through Other Approaches

By Waste Generator:

Medical Waste Management System for Hospitals

Medical Waste Management System for Clinics

Medical Waste Management System for Ambulatory Surgical Centers

Medical Waste Management System for Pharmaceutical Companies

Medical Waste Management System for Biotechnology Companies

Medical Waste Management System for Other Waste Generators

Cloud Based Drug Discovery Platform Market on the Rise: CAGR of 12.6% Expected, Worth US$ 2,424.33 Million by 2032

The Cloud Based Drug Discovery Platform Market is anticipated to grow at a rapid CAGR of 12.6% over the course of the forecast period. In 2022, the market will be worth US$ 2,424.33 Million. By the year 2032, it is predicted that the market for cloud-based drug discovery platforms will reach a high of US$ 7,529.59 Million.

A drug discovery platform is a place of research and development where medicines are identified for various diseases. Currently, the drug discovery platform is witnessing massive adoption of digital technologies. Cloud-based drug discovery platforms are gaining traction, as they give key players the opportunity to store huge data conveniently and in a cost-effective manner.

The benefits of cloud-based drug discovery platforms are enormous, and this is one of the key factors why it is gaining traction among end-users. This platform helps customers overcome many challenges by leveraging a network of web and mobile-accessible applications. It provides secure and collaborative project management and the ability to share project information. Moreover, the cloud-based drug discovery platform is flexible to offer end-users to customise it according to their projects.

Currently, cloud-based drug discovery platform is witnessing a period of technological advancement, as innovative features, such as publishing and sharing services are being offered to users. Cloud-based drug discovery platform is accessible through computers, notebook, and mobiles, and it is secure and can be maintained by a third party as well. Owing to all these factors, the cloud-based drug discovery platform market is anticipated to grow at a significant rate in terms of value.

Cloud-Based Drug Discovery Platform Market Dynamics

Data management is a critical issue for the pharmaceutical industry.  The pharmaceutical industry is rapidly restructuring its discovery business model to completely networked and integrated research and development in order to manage the huge data it generates. Storing this data on cloud not only offers cost savings, but also improved accessibility.

Graphical representation, a dynamic and quick form of getting results, helps in decision-making at a management level. Keeping the needs of consumers in mind, key players in the cloud-based drug discovery platform are offering flexible, cost-effective, and highly secure cloud-based storage options to consumers. Cloud-based drug discover platform runs at zero lag time, saving time and giving real-time access to users. This is another reason for the growing adoption of cloud-based drug discovery platform globally.

Confidentiality and privacy issues continue to impede the growth of the cloud-based drug discovery platform market. Although many improvements have been made in the recent past, cyber hacks continue to create apprehension among many pharma players, leading to stifled adoption.

North America, Japan and Western Europe regions are some of the key players in the global cloud-based drug discovery platform market. Many pharma companies based in these regions have already adopted cloud-based drug discovery platform, and it is anticipated that in the future, more companies will follow suit. The growth of the market in Asia Pacific excluding Japan (APEJ) is expected to gain momentum during the forecast period 2016-2026.

Cloud-Based Drug Discovery Platform Market Key Players:

Some of the key players operating in the cloud-based drug discovery platform market IBM Corp, Accenture PLC, BioXcel Corporation, Cloud Pharmaceuticals, Inc., WuXi AppTec (Shanghai) Co., Ltd., Dassault Systemes BIOVIA Ltd.

The report covers exhaustive analysis on:

Global Cloud-Based Drug Discovery Platform Market Segments

Global Cloud-Based Drug Discovery Platform Market Dynamics

Historical Actual Market Size, 2013 – 2015

Global Cloud-Based Drug Discovery Platform Market Size & Forecast 2016 to 2026

Supply & Demand Value Chain

Global Cloud-Based Drug Discovery Platform Market Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Global Cloud-Based Drug Discovery Platform Market Drivers and Restraints

Regional analysis for Global Cloud-Based Drug Discovery Platform Market includes

North America

US & Canada

Latin America

Brazil, Mexico, Others

Western Europe

EU5

Nordics

Benelux

Eastern Europe

Asia Pacific

Australia and New Zealand (ANZ)

Greater China

India

ASEAN

Rest of Asia Pacific

Japan

Middle East and Africa

GCC Countries

Other Middle East

North Africa

South Africa

Other Africa

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Cloud-Based Drug Discovery Platform Market Segmentation

On the basis of types of services, the cloud-based drug discovery platform market is segmented into

infrastructure as a Service (IaaS)

Platform as a Service (PaaS)

Software as a Service (SaaS)

Geographically, global cloud-based drug discovery market is segmented into 

North America

Latin America

Eastern Europe

Western Europe

Asia Pacific Excluding Japan (APEJ)

Japan

The Middle East and Africa (MEA)

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

Beyond Codes aims to provide your company with the resources and expertise it needs to survive in today's competitive environment. We offer various services- from B2B demand generation to lead generation and appointment setting.

Know more - https://beyondcodes.com/

Digital Therapeutics Market developing at a great 24.4% CAGR to arrive at US$ 42.5 Billion by 2032

As per Future Market Insights, the global Digital Therapeutics Market is forecast to reach US$ 4.8 Bn in 2022, with sales growing at an impressive 24.4% CAGR over the forecast period. The market size will reach US$ 42.5 Bn by 2032.
To infiltrate and disrupt the healthcare sector, IT companies are producing and acquiring digital therapies. Players are investigating whether digital medicines might improve quality of life and outcomes while maintaining or lowering total healthcare costs in certain disease areas, as well as how patient data obtained through such products can be used to determine coverage. To attract investors, start-ups are coming up with innovative digital therapeutic ideas.
Manufacturers are combining off-patent compounds with medical devices farther up the innovation spectrum, such as altering the mode of administration with better inhalers and auto-injectors. This necessitates a bigger investment in research and development, as well as greater usage of collaboration between molecule producers and device manufacturers.
Mass-market platforms present a significant possibility for interaction at scale. Manufacturers of consumer gadgets, namely smartphones and smartwatches, have included healthcare services and encouraged third-party developers to create apps for better patient outcomes.
Simultaneously, attempts have been made to improve the quality of available apps, with major app shops enforcing certain quality criteria. This is a beneficial development because it is critical to place a premium on the secure storage of research-grade data.
Owing to the above-mentioned factors, the digital therapeutics market will expand at a considerable pace over the assessment period.
“Increasing awareness regarding digital therapeutics across emerging economies, along with growing adoption of healthcare wearables will continue driving growth in the market over the forecast period,” says an FMI analyst.
Key Takeaways:
• Combination therapy as a solution is expected to account for an approximate market share value of 4% of the global market in 2022.
• By application, management is expected to hold a dominant market share value of 1% in the 2022 global market.
• Central nervous system disorders by indication displayed a CAGR growth value expected to reach 2% by 2032.
• Direct-to-patients/consumers is a dominant segment in terms of the business model within the global market, carrying an estimated market share value of about8%in 2022.
• The U.S. is accounted for 3% of the North America digital therapeutics market in 2021.
Key Players:
• Teladoc Health, Inc.
• Click Therapeutics, Inc.
• Welldoc
• HYGIEIA
• DarioHealth Corp
• BigHealth
• Orexo AB
• Akili Interactive Labs, Inc.
• Freespira
• Voluntis
• Kaia Health
• Kaiku Health
• Theranica Bio-Electronics Ltd.
• Propeller Health
• Orexo US, Inc.
• TALi Digital Limited
• Limbix Health, Inc.

Covid-19 Diagnostics Market to Scale New Heights, Anticipating US$204.51 Billion by 2032

The COVID-19 Diagnostics Market is positioned for exceptional growth, projecting a substantial climb to surpass the valuation of US$ 204.51 billion by 2032, driven by an impressive compound annual growth rate (CAGR) of 7.7%. This anticipated surge reflects the crucial role of diagnostic tools in managing the ongoing pandemic. As global efforts continue to combat COVID-19, this market’s exponential expansion underscores the significance of accurate and efficient testing solutions. The trajectory not only demonstrates the resilience of the healthcare sector but also the industry’s commitment to advancing diagnostic technologies in the face of unprecedented challenges.
The report features unique and salient factors that may make a huge impact on the development of the Covid-19 Diagnostics Market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the market in the years to come. The report provides detailed information about the current and future growth prospects of the market in the most comprehensive way for better understanding of readers.
Key Segments of Covid-19 Diagnostics Market
FMI’s study on the market offers information divided into four important segments— Drug Class, Route of Administration, Application, and Region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Key Takeaways from FMI’s Covid-19 Diagnostics Market Study
• Molecular assay holds the largest share right now and the trend is expected to continue till the end of 2020. This could be attributed to the fact that molecular assays have been looked upon as a gold standard to detect novel viral infections
• Diagnostic labs contributed to more than 60% of total market share in 2020’s first quarter
Key Challenges for Market Players & Researchers
Right now, the challenges faced include lack of information regarding the virus, like genetic information, biologics, duration of immunity in the recovered patients.
Certain treatment options that are expected to be potential game changers include ACE-Mab by Sorrento Therapeutics, HCQ (Hydroxychloroquine and chloroquine), Remdesivir antiviral by Gilead Sciences, and Canakinumab (Ilaris) by Novartis.
Moreover, options like cell-based therapies that involve natural killer cells or Mesenchymal stem cells and plasma therapies are on the verge of providing personalized treatment options.
Key Participant Insights
The key participants are focusing on acceleration of production as well as new product approval phase. For example – Novacyt Group, in Mar 2020, received EUA for 2-hour Covid-19 test. Also, in Apr 2020, CE approval was received by Abbott for IgG serology blood test for Covid-19.
The other players in the market include Veredus Laboratories, Thermo Fisher Scientific, Inc., Quidel Corporation, Perkin Elmer, Inc., Neuberg Diagnostics, Mylab Discovery Solutions Pvt Ltd., Luminex Corporation, Laboratory Corporation of America Holdings, Hologic Inc., Danaher, Cepheid, bioMérieux SA, Altona Diagnostics GmbH, ALDATU BIOSCIENCES, ADT Biotech Sdn Bhd, and 1drop Inc.
Key Segment
Product Type
• Instruments
• Test Kits
• Reagents and Consumables
Sample Type
• Oropharyngeal & Nasopharyngeal Swabs
• Blood
• Urine
• Others
Technology
• PCR
• ELISA
• POC
Region
• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa